Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics' stock price has been impacted by several events. In February 2026, the company reported strong commercial growth for the fourth quarter and full year 2025, but the stock dropped due to market concerns. The FDA accepted a Priority Review sNDA for AXS-05 for Alzheimer's disease agitation in December 2025. In April 2026, Axsome announced the acquisition of exclusive global rights to balipodect. Analyst ratings have been generally positive, but notable insider selling has been a watch item for investors. The company also agreed to a $7.75 million settlement in January 2026 to resolve allegations of misleading investors about regulatory risks for its migraine drug, AXS-07.

There is no explicit mention of significant demand seasonality for Axsome Therapeutics' products and services. Demand for treatments for chronic central nervous system disorders is generally considered to be relatively stable throughout the year. Prescription growth rates for Auvelity and Sunosi have been consistently reported without specific indications of seasonal peaks or troughs.

Axsome Therapeutics is a biopharmaceutical company focused on developing and delivering novel therapies for central nervous system (CNS) disorders. Its commercial product portfolio includes Auvelity for major depressive disorder (MDD), Sunosi for excessive daytime sleepiness, and Symbravo for acute migraine. The company's pipeline includes AXS-05 for Alzheimer's disease agitation and smoking cessation, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Axsome recently acquired exclusive global rights to balipodect for schizophrenia and Tourette syndrome.

Axsome Therapeutics primarily focuses its operations and market targeting within the United States, where its commercial products are marketed and sold. Auvelity generated significant sales in the United States in 2024, and both Auvelity and Sunosi have substantial U.S. payer coverage. The company has also expanded its market presence through a licensing transaction with Pharmanovia to market Sunosi in Europe and certain Middle East/North Africa countries.

Axsome Therapeutics has cultivated a positive brand reputation, driven by the strong commercial performance of its key products and advancements in its pipeline. The successful commercialization of Auvelity and consistent sales growth of Sunosi have contributed to this perception. Analyst sentiment is generally bullish, and the FDA's acceptance of a Priority Review for AXS-05 further enhances the company's reputation. However, the $7.75 million settlement in January 2026 related to allegations of misleading investors about the regulatory risks of its migraine drug, AXS-07, highlights past challenges.

Axsome Therapeutics is owned by a mix of institutional, insider, and retail investors. Institutional investors own approximately 73.58% of the stock, with major shareholders including Vanguard Group Inc, BlackRock, Inc., and Price T Rowe Associates Inc. Herriot Tabuteau, the CEO, is the largest individual shareholder, owning 28.73% of the company. Insiders collectively own about 45.09% of Axsome Therapeutics.